Recent Posts
- Dr. Scott L. Friedman Joins MAX BioPharma’s Scientific Advisory Board to Advance MASH Program
- MAX BioPharma and Technomark Life Sciences Announce Investment and Partnership Agreement in Developing Oxysterol-Based Drug Candidate for MASH
- MAX BioPharma and Revilico Announce Collaboration on Target Identification and Mechanistic Studies for Oxysterol Drug Candidates
- Oxy210 Reduces Senescence and Fibrosis in MASH Models
- Oxy210 Inhibits Atherosclerosis in Preclinical Models
Recent Comments
No comments to show.